Wall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to Hold

TransMedics Group (NASDAQ:TMDX) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts have also issued reports about the stock. Piper Sandler boosted their target price on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC increased their price objective on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Price Performance

TransMedics Group stock opened at $145.26 on Friday. The stock has a 50-day moving average price of $133.80 and a two-hundred day moving average price of $126.44. TransMedics Group has a 12 month low of $62.07 and a 12 month high of $156.00. The company has a market capitalization of $4.98 billion, a PE ratio of 29.64 and a beta of 2.06. The company has a current ratio of 7.14, a quick ratio of 7.13 and a debt-to-equity ratio of 1.06.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the transaction, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This trade represents a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of TransMedics Group during the third quarter valued at about $28,000. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group during the third quarter valued at about $29,000. Optiver Holding B.V. increased its position in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.